Forecast

There is no analyst data available for this company.

News Go to news feed

Moberg Pharma licenses MOB-015 to Karo Healthcare for marketing in 19 European markets

Moberg Pharma has signed an exclusive licensing agreement with Karo Healthcare to market its onychomycosis treatment MOB-015 (Terclara) in 19 European markets, including the United Kingdom. Karo will handle marketing, distribution and sales in Europe; the deal includes royalties and payments for supplied products, but financial details were not disclosed. The territory covers about 500 million people and includes 11 countries where Terclara is already approved but not yet launched. MOB-015 is a topical terbinafine formulation with a reported mycological cure rate of 76% and will, where possible, be marketed under the Lamisil brand; Karo is backed by KKR. Moberg emphasizes it will remain commercially active in other regions, notably the US, and analysis indicates it has solid liquidity despite not being profitable last year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2019, Moberg Pharma Aktie has already paid €41.79 in dividends. The last payout was in November 2019.

Financials

In the last quarter, Moberg Pharma Aktie had revenue of €520.31K and net profit of -€296.07K

(EUR)	Jun 2026	YoY
Revenue	520.31K	61.22%
Gross profit	340.01K	123.25%
Net profit	-296.07K	55.38%
EBITDA	-618.03K	16.50%

Fundamentals

Metric	Value
Market capitalization	€46.43M
Number of shares	47.18M
52-week high/low	€1.27 - €0.68
Dividends	No
Beta	0.73
P/E ratio	-23.80
PEG ratio	-0.18
P/B ratio	0.77
P/S ratio	30.74

Company profile

Moberg Pharma AB (publ), ein pharmazeutisches Unternehmen, entwickelt und vermarktet medizinische Produkte in Europa, den Vereinigten Staaten und international. Es entwickelt MOB-015, das eine klinische Studie der Phase III für die Behandlung von Nagelpilz abgeschlossen hat. Das Unternehmen war früher unter dem Namen Moberg Derma AB (publ) bekannt und änderte im Mai 2013 seinen Namen in Moberg Pharma AB (publ). Moberg Pharma AB (publ) wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Bromma, Schweden.